Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Colorectal Neoplasm
Interventions
DRUG

OS (oxalipaltin+S-1)

Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days

DRUG

XELOX (oxalipaltin+capecitabine)

Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days

Trial Locations (1)

431-070

Hallym University Medical Center, Anyang

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Hallym University Medical Center

OTHER

NCT00677144 - Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter